BEIR

Zeta Alpha Boosts GPT Reliability for Enterprise Search with its Powerful Semantic Neural Engine

Retrieved on: 
Tuesday, January 24, 2023

AMSTERDAM, Jan. 24, 2023 /PRNewswire/ -- Zeta Alpha, the neural search and discovery platform, today announced the company has launched an integration with OpenAI's GPT for its semantic neural search engine, resulting in significantly more reliable and explainable AI generated answers to enterprise search queries. This capability gives workers the unique ability to leverage the power of GPT to access knowledge hidden in troves of internal company data, an industry first.

Key Points: 
  • AMSTERDAM, Jan. 24, 2023 /PRNewswire/ -- Zeta Alpha , the neural search and discovery platform, today announced the company has launched an integration with OpenAI's GPT for its semantic neural search engine, resulting in significantly more reliable and explainable AI generated answers to enterprise search queries.
  • This is a real barrier preventing organizations from adopting AI tools for enterprise search and knowledge management.
  • The powerful combination of Zeta Alpha's intelligent neural search engine and advances in GPT-3 reduce this problem by applying natural language understanding at scale.
  • Notable enhancements to Zeta Alpha's search platform include:
    Breakthroughs in domain-specific search: Traditionally, enterprise search has been limited by a lack of training data.

Zeta Alpha Boosts GPT Reliability for Enterprise Search with its Powerful Semantic Neural Engine

Retrieved on: 
Tuesday, January 24, 2023

AMSTERDAM, Jan. 24, 2023 /PRNewswire/ -- Zeta Alpha, the neural search and discovery platform, today announced the company has launched an integration with OpenAI's GPT for its semantic neural search engine, resulting in significantly more reliable and explainable AI generated answers to enterprise search queries. This capability gives workers the unique ability to leverage the power of GPT to access knowledge hidden in troves of internal company data, an industry first.

Key Points: 
  • AMSTERDAM, Jan. 24, 2023 /PRNewswire/ -- Z eta Alpha , the neural search and discovery platform, today announced the company has launched an integration with OpenAI's GPT for its semantic neural search engine, resulting in significantly more reliable and explainable AI generated answers to enterprise search queries.
  • This is a real barrier preventing organizations from adopting AI tools for enterprise search and knowledge management.
  • The powerful combination of Zeta Alpha's intelligent neural search engine and advances in GPT-3 reduce this problem by applying natural language understanding at scale.
  • Notable enhancements to Zeta Alpha's search platform include:
    Breakthroughs in domain-specific search: Traditionally, enterprise search has been limited by a lack of training data.

Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

Retrieved on: 
Monday, October 25, 2021

SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.

Key Points: 
  • SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.
  • The addition of radiotherapy can extend survival that may be offset by the development of a secondary cancer like lung tumors many years following treatment.
  • This study reinforces the unparalleled accuracy of a 4-like robotic CyberKnife platform and shows its tremendous potential as a treatment for early-stage breast cancer," said Suzanne Winter, president at Accuray.
  • Breast cancer stage distribution and number of new cases were obtained from the North American Association of Central Cancer Registries (NAACCR).